Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19
Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, Chen R, Choudhury A, Henry A, Syndikus I, Mitin T, Tree A, Kishan AU, Spratt DE. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances In Radiation Oncology 2020, 5: 26-32. PMID: 33145460, PMCID: PMC7598436, DOI: 10.1016/j.adro.2020.10.003.Peer-Reviewed Original ResearchProstate cancerM1 diseaseNational Comprehensive Cancer Network risk groupClinical node-positive diseaseFavorable intermediate-risk diseaseRadiation therapy recommendationsIntermediate-risk diseaseNeoadjuvant hormone therapyNode-positive diseaseStage of diseaseTreatment of patientsProstate cancer stageRadiation oncology departmentsGlobal pandemicAdjuvant radiationModerate hypofractionationHormone therapyPositive diseaseRoutine visitsCancer stageTherapy recommendationsOncology departmentRisk groupsRadiation therapyTelemedicine consultationsProstate Cancer Radiation Therapy Recommendations in Response to COVID-19
Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, Chen R, Choudhury A, Henry A, Syndikus I, Mitin T, Tree A, Kishan AU, Spratt DE. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances In Radiation Oncology 2020, 5: 659-665. PMID: 32292839, PMCID: PMC7118610, DOI: 10.1016/j.adro.2020.03.010.Peer-Reviewed Original ResearchProstate cancerM1 diseaseNational Comprehensive Cancer Network risk groupClinical node-positive diseaseFavorable intermediate-risk diseaseRadiation therapy recommendationsIntermediate-risk diseaseNeoadjuvant hormone therapyNode-positive diseaseStage of diseaseTreatment of patientsProstate cancer stageRadiation oncology departmentsGlobal pandemicAdjuvant radiationModerate hypofractionationHormone therapyPositive diseaseRoutine visitsCancer stageTherapy recommendationsOncology departmentRisk groupsRadiation therapyTelemedicine consultations